SCHEMBL668764

SCHEMBL668764

Cc1cc(C)cc(C(=O)N(NC(=O)c2ccc3c(c2C)OCCO3)C(C)(C)C)c1

nearest known ligand 0.73

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 7/20 0.57
CYP3A4 P08684 2/20 0.50
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
HTT P42858 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8772458 0.91 ABCB1 (0.57) ABCB1CYP3A4CYP2C9CYP2C19HTT
SCHEMBL7476971 0.91 ABCB1 (0.50) ABCB1CYP3A4
SCHEMBL5062446 0.90 ABCB1 (0.56) ABCB1CYP3A4CYP2C9CYP2C19HTT
SCHEMBL7473520 0.90 ABCB1 (0.47) ABCB1CYP3A4
SCHEMBL7478126 0.89 ABCB1 (0.44) ABCB1
SCHEMBL5062563 0.88 ABCB1 (0.43) ABCB1
SCHEMBL668714 0.88 ABCB1 (0.55) ABCB1CYP3A4CYP2C9
SCHEMBL8998876 0.88 ABCB1 (0.57) ABCB1CYP3A4
SCHEMBL5053915 0.86 ABCB1 (0.43) ABCB1
SCHEMBL668088 0.86 ABCB1 (0.53) ABCB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7045315-B2 Methods for modulating expression of exogenous genes in mammalian systems THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2006-05-16 US claimed
US-20020187972-A1 Methods for modulating expression of exogenous genes in mammalian systems THE SALK INSTITUTE OF BIOLOGICAL STUDIES 2002-12-12 US claimed
EP-0496342-B2 New hydrazine derivative and pesticidal composition comprising said derivative as an effective ingredient NIPPON KAYAKU KK (JP) 2002-07-24 EP claimed
US-6333318-B1 USED IN THERAPY; FOR DELIVERING RECOMBINANT PROTEINS INTO A VARIETY OF CELLS WITHIN A PATIENT THE SALK INSTITUTE FOR BIOLOGICAL STUDIES 2001-12-25 US claimed
EP-0639559-B1 Preparation of 1,2-diacyl-2-(t-alkyl)hydrazines ROHM & HAAS (US) 1997-10-15 EP claimed
EP-0602794-A2 Insecticidal N'-substituted-N, N'-diacylhydrazines ROHM AND HAAS COMPANY (US) 1994-06-22 EP claimed
US-20210254056-A1 IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS CAMP4 THERAPEUTICS CORPORATION 2021-08-19 US disclosed
US-10851119-B2 Boron-containing diacylhydrazines INTREXON CORPORATION (US) 2020-12-01 US disclosed
US-20200157122-A1 BORON-CONTAINING DIACYLHYDRAZINES INTREXON CORP (US) 2020-05-21 US disclosed
US-10464951-B2 Boron-containing diacylhydrazines INTREXON CORPORATION (US) 2019-11-05 US disclosed
US-20180079759-A1 Boron-Containing Diacylhydrazines INTREXON CORPORATION (US) 2018-03-22 US disclosed
US-20180079759-A1 Boron-Containing Diacylhydrazines INTREXON CORPORATION (US) 2018-03-22 US disclosed
EP-1601642-B1 BIOAVAILABLE DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX INTREXON CORP (US) 2017-01-04 EP disclosed
EP-0639559-B1 Preparation of 1,2-diacyl-2-(t-alkyl)hydrazines ROHM & HAAS (US) 1997-10-15 EP disclosed
EP-0729934-A2 A process for producing a 3-alkoxy-2-(substituted)benzoic acid or an ester thereof ROHM AND HAAS COMPANY (US) 1996-09-04 EP disclosed
EP-0729953-A2 A process for producing a 2-substituted-3,4-fused heterocyclic benzoic acid ROHM AND HAAS COMPANY (US) 1996-09-04 EP disclosed
US-5530028-A CONTROLS INSECTS OF THE ORDER LEPIDOPTERA ROHM AND HAAS COMPANY (US) 1996-06-25 US disclosed
US-5530021-A AGRICULTURAL INSECTICIDES NIPPON KAYAKU KABUSHIKI KAISHA (JP) 1996-06-25 US disclosed
US-5378726-A Insecticide, parasiticide NIPPON KAYAKU KABUSHIKI KAISHA (JP) 1995-01-03 US disclosed
EP-0602794-A2 Insecticidal N'-substituted-N, N'-diacylhydrazines ROHM AND HAAS COMPANY (US) 1994-06-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10464951-B2 Boron-containing diacylhydrazines CD22, BRDT, BCR ABCB1 464/4885CYP3A4 3689/4885CYP2C9 4175/4885
US-20020187972-A1 Methods for modulating expression of exogenous genes in mammalian systems NR2E3, GFRA2, GFRA3 ABCB1 3049/4885CYP3A4 4624/4885CYP2C9 4751/4885
US-10851119-B2 Boron-containing diacylhydrazines CD22, BRDT, BCR ABCB1 464/4885CYP3A4 3689/4885CYP2C9 4175/4885
US-20200157122-A1 BORON-CONTAINING DIACYLHYDRAZINES CD22, BRDT, BCR ABCB1 464/4885CYP3A4 3689/4885CYP2C9 4175/4885
US-20180079759-A1 Boron-Containing Diacylhydrazines CD22, BRDT, BCR ABCB1 464/4885CYP3A4 3689/4885CYP2C9 4175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.